Plasmalyte 148 + Glucose 5 % w/v Viaflo inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plasmalyte 148 + glucose 5 % w/v viaflo inf. sol. i.v.

baxter sa-nv - sodium acetate trihydrate 3,68 g/l; potassium chloride 370 µg/ml; magnesium chloride hexahydrate 300 µg/ml; sodium gluconate 5,02 mg/ml; sodium chloride 5,26 mg/ml; glucose monohydrate 55 mg/ml - solution for infusion - glucose monohydrate 55 mg/ml; magnesium chloride hexahydrate 300 µg/ml; potassium chloride 370 µg/ml; sodium gluconate 5.02 mg/ml; sodium chloride 5.26 mg/ml; sodium acetate trihydrate - electrolytes with carbohydrates

Plasmalyte A Viaflo inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plasmalyte a viaflo inf. sol. i.v.

baxter sa-nv - sodium acetate trihydrate 3,68 g/l; potassium chloride 370 µg/ml; magnesium chloride hexahydrate 300 µg/ml; sodium gluconate 5,02 mg/ml; sodium chloride 5,26 mg/ml - solution for infusion - magnesium chloride hexahydrate 300 µg/ml; potassium chloride 370 µg/ml; sodium acetate trihydrate; sodium gluconate 5.02 mg/ml; sodium chloride 5.26 mg/ml - electrolytes

Plasmalyte 148 + Glucose 5 % w/v Viaflo inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plasmalyte 148 + glucose 5 % w/v viaflo inf. sol. i.v.

baxter sa-nv - sodium acetate trihydrate 3,68 g/l; potassium chloride 370 µg/ml; magnesium chloride hexahydrate 300 µg/ml; sodium gluconate 5,02 mg/ml; sodium chloride 5,26 mg/ml; glucose monohydrate 55 mg/ml - solution for infusion - electrolytes with carbohydrates

Plasmalyte 148 + Glucose 5 % w/v Viaflo inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plasmalyte 148 + glucose 5 % w/v viaflo inf. sol. i.v.

baxter sa-nv - sodium acetate trihydrate 3,68 g/l; potassium chloride 370 µg/ml; magnesium chloride hexahydrate 300 µg/ml; sodium gluconate 5,02 mg/ml; sodium chloride 5,26 mg/ml; glucose monohydrate 55 mg/ml - solution for infusion - electrolytes with carbohydrates

Plasmalyte A Viaflo inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plasmalyte a viaflo inf. sol. i.v.

baxter sa-nv - sodium acetate trihydrate 3,68 g/l; potassium chloride 370 µg/ml; magnesium chloride hexahydrate 300 µg/ml; sodium gluconate 5,02 mg/ml; sodium chloride 5,26 mg/ml - solution for infusion - electrolytes

POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE- potassium chloride, dextrose monohydrate and sodium chloride injection, solu United States - English - NLM (National Library of Medicine)

potassium chloride in dextrose and sodium chloride- potassium chloride, dextrose monohydrate and sodium chloride injection, solu

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - potassium chloride 150 mg in 100 ml - potassium chloride in dextrose and sodium chloride injection is indicated as a source of water, electrolytes and calories. potassium chloride in dextrose and sodium chloride injection is contraindicated in patients with: risk summary appropriate administration of potassium chloride in dextrose sodium chloride injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with potassium chloride in dextrose sodium chloride injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary sodium and potassium are present in human breast milk. there are no data on the effects

Ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, Injection for intravenous infusion 1000 mL Freeflex bag Australia - English - Department of Health (Therapeutic Goods Administration)

ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, injection for intravenous infusion 1000 ml freeflex bag

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

SUFLAVE- polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution United States - English - NLM (National Library of Medicine)

suflave- polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution

braintree laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium sulfate anhydrous (unii: ml30mj2u7i) (magnesium cation - unii:t6v3lhy838), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698) - suflave is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. suflave is contraindicated in the following conditions: - gastrointestinal obstruction or ileus [see warnings and precautions ( 5.6)] - bowel perforation [see warnings and precautions ( 5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any ingredient in suflave  [see warnings and precautions ( 5.8)] risk summary there are no available data on the use of suflave during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride (suflave). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other ad

Ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, Injection for intravenous infusion 500 mL Freeflex bag Australia - English - Department of Health (Therapeutic Goods Administration)

ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, injection for intravenous infusion 500 ml freeflex bag

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

SODIUM ACETATE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium acetate injection, solution, concentrate

hospira, inc. - sodium acetate anhydrous (unii: nvg71zz7p0) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium acetate anhydrous 164 mg in 1 ml - sodium acetate injection, usp (2 meq/ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (2 meq/ml) is contraindicated in patients with hypernatremia or fluid retention.